JP2002525330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525330A5 JP2002525330A5 JP2000571926A JP2000571926A JP2002525330A5 JP 2002525330 A5 JP2002525330 A5 JP 2002525330A5 JP 2000571926 A JP2000571926 A JP 2000571926A JP 2000571926 A JP2000571926 A JP 2000571926A JP 2002525330 A5 JP2002525330 A5 JP 2002525330A5
- Authority
- JP
- Japan
- Prior art keywords
- pamoate
- compound
- olanzapine
- equation
- typical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- ZIMCQJVMPKQQPB-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine hydrate Chemical compound O.CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12.OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O ZIMCQJVMPKQQPB-UHFFFAOYSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229960001072 olanzapine pamoate Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229960004800 olanzapine pamoate monohydrate Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16376898A | 1998-09-30 | 1998-09-30 | |
| US09/163,768 | 1998-09-30 | ||
| US09/163,769 | 1998-09-30 | ||
| US09/163,769 US6169084B1 (en) | 1997-09-30 | 1998-09-30 | 2-methyl-thieno-benzodiazepine formulation |
| PCT/US1999/006417 WO2000018408A1 (en) | 1998-09-30 | 1999-03-24 | 2-methyl-thieno-benzodiazepine formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002525330A JP2002525330A (ja) | 2002-08-13 |
| JP2002525330A5 true JP2002525330A5 (OSRAM) | 2006-05-11 |
| JP4551988B2 JP4551988B2 (ja) | 2010-09-29 |
Family
ID=26859927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000571926A Expired - Lifetime JP4551988B2 (ja) | 1998-09-30 | 1999-03-24 | ２−メチル−チエノ−ベンゾジアゼピン製剤 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1119359B1 (OSRAM) |
| JP (1) | JP4551988B2 (OSRAM) |
| CN (1) | CN1146422C (OSRAM) |
| AT (2) | ATE359793T1 (OSRAM) |
| AU (1) | AU759751B2 (OSRAM) |
| BR (1) | BR9914156A (OSRAM) |
| CA (1) | CA2344873A1 (OSRAM) |
| CZ (1) | CZ302367B6 (OSRAM) |
| DE (2) | DE69917663T2 (OSRAM) |
| DK (2) | DK1468689T3 (OSRAM) |
| EA (1) | EA002580B1 (OSRAM) |
| ES (2) | ES2221376T3 (OSRAM) |
| GE (1) | GEP20094818B (OSRAM) |
| HK (1) | HK1041199B (OSRAM) |
| HR (1) | HRP20010238B1 (OSRAM) |
| HU (1) | HU227400B1 (OSRAM) |
| ID (1) | ID29574A (OSRAM) |
| IL (2) | IL141766A0 (OSRAM) |
| MY (1) | MY126476A (OSRAM) |
| NO (1) | NO328243B1 (OSRAM) |
| NZ (1) | NZ510208A (OSRAM) |
| PL (1) | PL196821B1 (OSRAM) |
| PT (2) | PT1468689E (OSRAM) |
| SK (1) | SK285944B6 (OSRAM) |
| TR (1) | TR200100885T2 (OSRAM) |
| TW (1) | TW577890B (OSRAM) |
| UA (1) | UA66872C2 (OSRAM) |
| WO (1) | WO2000018408A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| WO2001047933A1 (en) * | 1999-12-28 | 2001-07-05 | Cipla Limited | New polymorphic forms of olanzapine |
| PL196814B1 (pl) * | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| ES2289974T1 (es) * | 2004-07-14 | 2008-02-16 | Shasun Chemicals And Drugs Limited | Metodo mejorado para producir la forma i de la olanzapina. |
| ES2253091B1 (es) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
| AU2005307797B2 (en) * | 2004-11-16 | 2011-06-02 | Alkermes Pharma Ireland Limited | Injectable nanoparticulate olanzapine formulations |
| US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| EP1838716B1 (en) * | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| CZ299218B6 (cs) * | 2006-11-07 | 2008-05-21 | Zentiva, A. S. | Kompozice depotních olanzapinových injekcních systému |
| FR2927965B1 (fr) * | 2008-02-22 | 2010-06-04 | Valeo Materiaux De Friction Sa | Procede de fabrication d'un materiau de friction et notamment d'une couronne de friction d'embrayage. |
| US9314509B2 (en) * | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| WO2011091142A2 (en) * | 2010-01-20 | 2011-07-28 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous forms of olanzapine pamoate |
| CN107595771A (zh) | 2010-10-18 | 2018-01-19 | 大日本住友制药株式会社 | 注射用缓释制剂 |
| EP2956456B1 (en) | 2013-02-13 | 2017-07-12 | Neuland Laboratories Ltd | A process for preparation of olanzapine pamoate |
| CN105044231B (zh) * | 2015-06-27 | 2022-09-13 | 万特制药(海南)有限公司 | 一种分离测定奥氮平双羟萘酸盐一水合物有关物质的方法 |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2095499A1 (en) * | 1992-05-08 | 1993-11-09 | Petrus J. M. Van Den Oetelaar | Depot preparation |
| ATE188375T1 (de) * | 1992-11-17 | 2000-01-15 | Yoshitomi Pharmaceutical | Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
| TR199900639T2 (xx) * | 1996-09-23 | 1999-06-21 | Eli Lilly And Company | Olanzapin dihidrat D. |
| CA2304568C (en) * | 1997-09-30 | 2008-08-12 | Eli Lilly And Company | Olanzapine pamoate formulations |
-
1999
- 1999-03-24 DE DE69917663T patent/DE69917663T2/de not_active Expired - Lifetime
- 1999-03-24 NZ NZ510208A patent/NZ510208A/xx not_active IP Right Cessation
- 1999-03-24 EA EA200100406A patent/EA002580B1/ru not_active IP Right Cessation
- 1999-03-24 ES ES99915009T patent/ES2221376T3/es not_active Expired - Lifetime
- 1999-03-24 JP JP2000571926A patent/JP4551988B2/ja not_active Expired - Lifetime
- 1999-03-24 AT AT04005832T patent/ATE359793T1/de active
- 1999-03-24 TR TR2001/00885T patent/TR200100885T2/xx unknown
- 1999-03-24 CN CNB998115355A patent/CN1146422C/zh not_active Expired - Lifetime
- 1999-03-24 ES ES04005832T patent/ES2285294T3/es not_active Expired - Lifetime
- 1999-03-24 PT PT04005832T patent/PT1468689E/pt unknown
- 1999-03-24 GE GEAP199911232A patent/GEP20094818B/en unknown
- 1999-03-24 DK DK04005832T patent/DK1468689T3/da active
- 1999-03-24 EP EP99915009A patent/EP1119359B1/en not_active Expired - Lifetime
- 1999-03-24 DE DE69935873T patent/DE69935873T2/de not_active Expired - Lifetime
- 1999-03-24 PT PT99915009T patent/PT1119359E/pt unknown
- 1999-03-24 WO PCT/US1999/006417 patent/WO2000018408A1/en not_active Ceased
- 1999-03-24 AU AU33627/99A patent/AU759751B2/en not_active Expired
- 1999-03-24 CZ CZ20011149A patent/CZ302367B6/cs not_active IP Right Cessation
- 1999-03-24 CA CA002344873A patent/CA2344873A1/en not_active Withdrawn
- 1999-03-24 BR BR9914156-6A patent/BR9914156A/pt not_active Application Discontinuation
- 1999-03-24 DK DK99915009T patent/DK1119359T3/da active
- 1999-03-24 UA UA2001032118A patent/UA66872C2/uk unknown
- 1999-03-24 ID IDW20010679A patent/ID29574A/id unknown
- 1999-03-24 SK SK416-2001A patent/SK285944B6/sk not_active IP Right Cessation
- 1999-03-24 IL IL14176699A patent/IL141766A0/xx active IP Right Grant
- 1999-03-24 HU HU0103636A patent/HU227400B1/hu unknown
- 1999-03-24 AT AT99915009T patent/ATE267602T1/de active
- 1999-03-24 PL PL346981A patent/PL196821B1/pl unknown
- 1999-03-24 HK HK02100774.0A patent/HK1041199B/en not_active IP Right Cessation
- 1999-03-24 HR HR20010238A patent/HRP20010238B1/xx not_active IP Right Cessation
- 1999-03-30 MY MYPI99001217A patent/MY126476A/en unknown
- 1999-04-02 TW TW088105028A patent/TW577890B/zh not_active IP Right Cessation
-
2001
- 2001-03-01 IL IL141766A patent/IL141766A/en not_active IP Right Cessation
- 2001-03-28 NO NO20011583A patent/NO328243B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1797878A3 (en) | Benzothiazole derivatives | |
| JP2002508352A5 (ja) | ４(３)置換−４(３)−アミノメチル−（チオ）ピラン又はピペリジン誘導体（＝ガバペンチン類似体） | |
| WO2002055017A3 (en) | Method of treating autoimmune diseases | |
| HUP9701694A3 (en) | Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds | |
| JP2003531821A5 (OSRAM) | ||
| JP2006507220A5 (OSRAM) | ||
| JP2002518502A5 (OSRAM) | ||
| EP1246622A4 (en) | NEW SUBSTITUTED DOSE FORMS OF BENZIMIDAZOLENES AND METHOD FOR THE USE THEREOF | |
| JP2003531118A5 (OSRAM) | ||
| MA26757A1 (fr) | Preparation pharmaceutique de moxifloxacine | |
| KR880003958A (ko) | 신규 세펨화합물 및 그의 제조방법 | |
| BG106509A (en) | Preparative form | |
| IL153428A (en) | Solid Velcartan Pharmaceuticals | |
| JP2002522501A5 (OSRAM) | ||
| IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
| CA2126118A1 (en) | 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative | |
| WO2004029064A8 (en) | (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof | |
| EP1101769A3 (en) | Nitrogen containing erythromycin derivatives | |
| HUT73788A (en) | Glycopyranoside benzothiophenes, pharmaceutical comns. contg. them and process to prepare the said compds. | |
| JP2006510659A5 (OSRAM) | ||
| EP1253139A3 (en) | Multioligoanilinated fullerenes | |
| YU133383A (en) | Process for obtaining a new tetrahydro-5,6,7,7a-4h-thieno(3,2-c)-pyridione-2 | |
| HUP0301205A3 (en) | Use of pamoic acid, its derivatives and its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates and process for preparation of the compounds | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
| HUP0201301A3 (en) | Polymorphs of a crystalline azabicyclo(2,2,2)octan-3-amine citrate and their pharmaceutical compositions and process for preparation of the compounds |